Hycanthone

Cas No.:	3105-97-3
Chemical Name:	9H-Thioxanthen-9-one,1-[[2-(diethylamino)ethyl]amino]-4-(hydroxymethyl)-
Synonyms:	9H-Thioxanthen-9-one,1-[[2-(diethylamino)ethyl]amino]-4-(hydroxymethyl)-;1-[(2-[DIETHYLAMINO]ETHYL)AMINO]-4-[HYDROXYMETHYL]-9H-THIOXANTHEN-9-ONE;Hycanthone;1-((2-(diethylamino)ethyl)amino)-4-(hydroxymethyl)-9h-thioxanthen-9-on;1-((2-(diethylamino)ethyl)amino)-4-(hydroxymethyl)thioxanthen-9-one;1-(2-diethylaminoethylamino)-4-methylol-thioxanthen-9-one;ETRENOL;Etrenol(mesylate);hycanthon;lucanthonemetabolite;Win 249-33;1-((2-(Diethylamino)ethyl)amino)-4-(hydroxymethyl)-9H-thioxanthen-9-one
SMILES:	O=C1C2=C(SC3=C1C=CC=C3)C(CO)=CC=C2NCCN(CC)CC
Formula:	C20H24N2O2S
M.Wt:	356.48176
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Hycanthone is an effective antischistosomai drug.
In Vivo:	Results show that the incorporation of tritiated thymidine into TCA-precipitable material of adult sensitive worms undergo a progressive decrease after treatment with Hycanthone. Immature worms are totally unaffected by Hycanthone at all times tested. Male worms treated with Hycanthone show signs of a possible partial recovery from the initial low levels of incorporation. The incorporation of tritiated leucine by drug-sensitive worms treated with Hycanthone is inhibited by 40 to 50% in the first four days after treatment. Results show that, 7 days after Hycanthone treatment, both ribosomal RNA species are reduced by at least 80% with respect to untreated worms, with some indication of a possible accumulation of heavier precursor molecules[1].
In Vitro:	Hycanthone at 20 mg/mL or more is progressively more detrimental to cell viability. Results reveal that increased concentrations of Hycanthone, ranging from 0.1 to 10 μg/mL, progressively reduces viral interferon yields as much as 73% compare to that of controls[2].
Cell Assay:	Appropriate quantities of Hycanthone (1 to 100 μg) in 10 mL maintenance medium are added to plastic flasks (75 cm2) containing approximately 3×107 LLC-MK2 cells in monolayer, which are then incubated at 35°C for 24 h. Maintenance medium is decanted, and 2 mL influenza virus is added onto cell monolayers and incubated at 35°C for 2 h. The multiplicity of infection is approximately 1.0. Inoculum is removed and 10 mL maintenance medium is added to each flask, which is then incubated at 35°C for 24 h. Supernatant fluid is decanted, centrifuged at 100,000 g for 1 h, dialyzed against HCI-KCI buffer (pH 2.0) at 4°C for 24 h, and then dialyzed against two changes of phosphate-buffered saline (pH 7.1) at 4°C for 24 h. Fluids are passed through filters to obtain sterile preparations. Samples are stored at -80°C until assayed for interferon activity[2].
Animal Administration:	Female outbred Swiss albino mice used as definitive hosts weigh 18 to 20 g at the time of infection. Hycanthone is administered at 0.01 mL/g body weight intramuscularly by splitting the dose into the two hind legs, so that each mouse receives 80 mg/kg body weight of the free base. Treatments are usually performed during the 8th week after infection[1].
References:	[1]. Pica Mattoccia L, et al. Effect of hycanthone administered in vivo upon the incorporation of radioactive precursors into macromolecules of Schistosoma mansoni. Mol Biochem Parasitol. 1983 Jun;8(2):99-107. [2]. Hahon N, et al. Action of antischistosomal drugs, hycanthone and its analog 1A-4 N-oxide, on viral interferon induction. J Toxicol Environ Health. 1980 Jul;6(4):705-12.